行情

XXII

XXII

22ND CENTURY
AMEX

实时行情|Nasdaq Last Sale

4.600
-0.190
-3.97%
盘前: 4.610 +0.01 +0.22% 09:17 06/15 EDT
开盘
4.780
昨收
4.790
最高
4.860
最低
4.590
成交量
5,646
成交额
--
52周最高
6.07
52周最低
0.5500
市值
7.48亿
市盈率(TTM)
-31.1231
分时
5日
1月
3月
1年
5年
大麻周:联邦研究法案,乔治洛佩兹,巴西,摩洛哥,哥伦比亚护理等
As we near the end of the first half of 2021, we can see cannabis stocks traded mostly up by double digits, with the Amplify Seymour Cannabis ETF (NYSE: CNBS) delivering gains of more than 50% year-to-date. This week, however, stocks posted mixed performan...
Benzinga · 3天前
22nd Century Group 完成注册直接发售,融资 4000 万美元
Plant-based biotech company 22nd Century Group, Inc. (NYSE AMEX: XXII) has raised $40 million through a previously announced registered direct offering of its 10 million common shares at $4.00 per share. The Buffalo, New York-based company closed the offer...
Benzinga · 4天前
简报 - Emery Asset Management Lp 报告称,截至 6 月 7 日,22Nd Century Group 持有 6.23% 的被动股权
reuters.com · 4天前
22nd Century Group 完成普通股直接发售
MT Newswires · 5天前
22nd Century Group 加入罗素 2000、罗素 3000、罗素全球指数
MT Newswires · 5天前
自 2021 年 6 月 7 日起大麻股票的上涨和下跌
GAINERS: Marrone Bio Innovations (NASDAQ: MBII) shares closed up 13.33% at $1.53
Benzinga · 06/07 20:54
22nd Century Group 旗下 Cannabis Research Co. 的股票在 Cowen and Company 的 4000 万美元注册直接发行中小幅上涨
Plant-based biotech company 22nd Century Group, Inc. (NYSE AMEX: XXII) announced Monday it will raise $40 million via a registered direct offering with one institutional investor.
Benzinga · 06/07 19:14
简报--22 世纪推进计划以加强和最大化大麻/大麻特许经营的收入机会
reuters.com · 06/07 14:55
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解XXII最新的财务预测,通过XXII每股收益,每股净资产,每股现金流等数据分析22ND CENTURY近期的经营情况,然后做出明智的投资选择。
分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测XXII价格均价为7.00,最高价位7.00,最低价为7.00。
EPS
机构持股
总机构数: 110
机构持股: 3,563.03万
持股比例: 21.92%
总股本: 1.63亿
类型机构数股数
增持
26
114.86万
建仓
10
1,115.84万
减持
24
72.62万
平仓
14
34.58万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
环保服务及设备
+0.01%
专业与商业服务
+0.52%
高管信息
Chairman/Director
Nora Sullivan
President/Chief Operating Officer
Michael Zercher
Chief Executive Officer
James Mish
Chief Financial Officer
John Franzino
Vice President
John Brodfuehrer
Vice President
Lisa Parks
Vice President - Research & Development
Juan Tamburrino
Director of Investor Relations
Mei Kuo
Independent Director
Michael Koganov
Independent Director
Roger O'Brien
Independent Director
Richard Sanders
暂无数据
XXII 简况
22nd Century Group, Inc. is a plant biotechnology company. The Company is focused on technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and levels of cannabinoids in cannabis plants through genetic engineering and plant breeding. It is engaged in various activities, including research and development of less harmful or modified risk tobacco products and tobacco plant varieties; development of X-22, a smoking cessation aid consisting of very low nicotine (VLN) cigarettes; manufacture, marketing and distribution of its RED SUN and MAGIC cigarettes; production of SPECTRUM research cigarettes for the National Institute on Drug Abuse (NIDA); contract manufacturing of third-party branded tobacco products, and research and development of plant varieties of hemp/cannabis, such as plants with low to no amounts of delta-9-tetrahydrocannabinol (THC), plants with high levels of cannabidiol (CBD), and other non-THC cannabinoids.

微牛提供22nd Century Group Inc(AMEX-XXII)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的XXII股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易XXII股票基本功能。